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Eukaryotic high-mobility-group-box (HMGB) proteins are nuclear factors involved in chromatin remodeling and transcription
regulation. When released into the extracellular milieu, HMGB1 acts as a proinflammatory cytokine that plays a central role in
the pathogenesis of several immune-mediated inflammatory diseases. We found that the Plasmodium genome encodes two gen-
uine HMGB factors, PlasmodiumHMGB1 and HMGB2, that encompass, like their human counterparts, a proinflammatory do-
main. Given that these proteins are released from parasitized red blood cells, we then hypothesized that PlasmodiumHMGB
might contribute to the pathogenesis of experimental cerebral malaria (ECM), a lethal neuroinflammatory syndrome that devel-
ops in C57BL/6 (susceptible) mice infected with Plasmodium berghei ANKA and that in many aspects resembles human cerebral
malaria elicited by P. falciparum infection. The pathogenesis of experimental cerebral malaria was suppressed in C57BL/6 mice
infected with P. berghei ANKA lacking the hmgb2 gene (hmgb2 ANKA), an effect associated with a reduction of histological
brain lesions and with lower expression levels of several proinflammatory genes. The incidence of ECM in pbhmgb2-deficient
mice was restored by the administration of recombinant PbHMGB2. Protection from experimental cerebral malaria inhmgb2
ANKA-infected mice was associated with reduced sequestration in the brain of CD4 and CD8 T cells, including CD8 gran-
zyme B and CD8 IFN- cells, and, to some extent, neutrophils. This was consistent with a reduced parasite sequestration in
the brain, lungs, and spleen, though to a lesser extent than in wild-type P. berghei ANKA-infected mice. In summary, Plasmo-
diumHMGB2 acts as an alarmin that contributes to the pathogenesis of cerebral malaria.
Malaria, the disease caused by Plasmodium infection, accountsfor an estimated 660,000 deaths per year, mainly in sub-
Saharan African regions (1). Among the five Plasmodium subspe-
cies infecting humans, Plasmodium falciparum is the most preva-
lent in these regions, where it can cause the development of
clinical symptoms ranging from asymptomatic or flu-like illness
to the so-called severe forms ofmalaria, which include severe ane-
mia, respiratory distress, acidosis, multiorgan failure, and, even-
tually, cerebral malaria (2, 3). Of these clinical outcomes, cerebral
malaria (CM) is the most common, is fatal, and occurs mainly in
children under the age of 5 years (for a review, see references 3 and
4). There is currently no cure for CM, and therefore, identification
and functional characterization of host and parasite molecules
involved in the pathogenesis of this disease are of major impor-
tance, as they could lead to the development of new therapeutic
interventions.
The molecular mechanisms underlying the pathogenesis of
CM remain poorly understood. Presumably, sequestration of par-
asitized red blood cells (pRBCs) in the brain microvasculature, in
association with a systemic inflammation with production of free
radicals and proinflammatory cytokines, is critical to the onset of
this disease. While several host genes, encoding, e.g., cytokines,
chemokines, and adhesion molecules (5–8), and the products of
hemoglobin degradation (9–11) have been implicated in the
pathogenesis of CM as related to the proinflammatory nature of
the host immune response, the individual contributions of genes
encoded by Plasmodium to the onset of CM are less clear. Re-
cently, some Plasmodium proteins were reported to play a role in
severe malaria. First, in human malaria, the expression of several
specific PfEMP1 proteins promoted cytoadherence to brain endo-
thelial cells and correlated with the severity of cerebral malaria
(12, 13), suggesting that these proteins constitute a major viru-
lence factor for cerebral malaria. Second, in rodents, the plasmep-
sin-4 (pm4) gene, encoding an aspartic protease involved in he-
moglobin digestion, was shown to be implicated in experimental
cerebral malaria (ECM) (14, 15). Finally, several studies also re-
ported a crucial role for ICAM-1 in malaria pathogenesis, and
notably, ICAM-1-deficient mice are protected from ECM (16).
The combined effect of these pathological events is associatedwith
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disruption of the physical integrity of the blood-brain barrier
(BBB) and the development of brain edema, leading to coma and,
ultimately, death (2, 17–20). One of the characteristic features of
ECM is the increased sequestration of CD4 and CD8 T cells,
which have been reported to be associated with disease pathogen-
esis (21, 22). More recently, a subpopulation of CD8 T cells
expressing granzymeB (GzmB)was found to be critically involved
in ECM (23) and was associated with the parasite burdens within
the brains of C57BL/6 mice infected with P. berghei ANKA para-
sites (24). This finding underlines a direct link occurring in the
brain between parasite load and CD8 T-cell recruitment and the
accumulation of products of hemoglobin oxidation in the patho-
genesis of ECM. Proinflammatory cytokines, such as gamma in-
terferon (IFN-), have been shown to be implicated in the patho-
genesis of ECM(25, 26). The production of interleukin-6 (IL-6) in
response to tumor necrosis factor alpha (TNF-) by endothelial
cells of brain capillaries was also reported for mice genetically
sensitive to CM development (27). More recently, various reports
showed that type I IFN governs cerebral malaria (28). High-mo-
bility-group-box (HMGB) proteins are nuclear proteins origi-
nally shown to be loosely associated with DNA and to participate,
at least to some extent, in the regulation of gene transcription (for
a review, see references 29 and 30). Subsequent studies showed
that the humanHMGB (huHMGB) proteins are composed of two
HMGB domains, box A and box B, in tandem, and that the
HMGB1 isoform is actively secreted from activated innate im-
mune cells, namely, macrophages (31), and can be released from
injured cells (32) as well. In humans, HMGB1 has an important
role as an extracellular soluble protein that signals tissue injury
and initiates an inflammatory response. This “alarmin” protein is
considered a danger signal that alerts the innate immune system to
trigger a defensive and inflammatory response. Indeed, once re-
leased, extracellular HMGB1 becomes associated with a variety of
endogenous ligands that are recognized by several pattern recog-
nition receptors, including members of the Toll-like receptor
(TLR) family as well as the receptor for advanced glycation end
products (RAGE) (33). This explains the ability of HMGB1 to
trigger inflammatory responses (34) contributing to the patho-
genesis of inflammatory disorders (35). Plasma or serumHMGB1
levels were increased in patients with sepsis (36, 37), hemorrhagic
shock (38), or trauma (39), and high circulating levels of HMGB1
are often associated with critical illness (40, 41). This proinflam-
matory effect has beenmapped to a single 20-amino-acid domain
of box B of the mammalian protein that alone bears the proin-
flammatory activity of this protein (42). Moreover, huHMGB1
can promote vascular permeability, leading to edema (43). Pre-
sumably, the combined proinflammatory and vasoactive effects of
HMGB1 participate subsequently to the establishment of an am-
plification loop (44), which explains the involvement of the pro-
tein in the pathogenesis of a variety of immune-mediated inflam-
matory diseases. Inmalaria, the huHMGB1 serum levels evaluated
in P. falciparum-infected children who developed fatal cases of
CM were significantly higher than those for uncomplicated ma-
laria cases (45, 46), suggesting that as for other immune-mediated
inflammatory diseases, HMGB1 might also be involved in the
pathogenesis of CM.
Considering the established role of human HMGB proteins in
the pathogenesis of several inflammatory diseases, we hypothe-
sized that Plasmodium HMGB proteins might contribute to in-
flammation during severe malaria. Among these disorders, CM is
defined as a lethal outcome of Plasmodium infection that is fre-
quently associated with multiple-organ failure (47).
We previously showed that several Plasmodium genes encod-
ing transcription-associated proteins (TAPs) implicated in chro-
matin remodeling (48) include the genes for the HMGB isoform
orthologues PfHMGB1 and PfHMGB2 (49). As for mammalian
HMGB proteins, in Plasmodium there are two HMGB proteins,
HMGB1 and HMGB2, which consist of only one HMGB domain
and also comprise a 20-amino-acid peptide potentially bearing the
proinflammatory activity. In keeping with this notion, P. falcipa-
rum HMGB proteins are released into culture medium and pres-
ent in the plasmas of infected C57BL/6 mice, and a recombinant
protein was shown to induce TNF- and L-6 production (50).
Since we consider that cerebral vascular obstruction and systemic
inflammation probably combine to trigger cerebral malaria, we
studied the role of parasitic HMGB proteins in the onset of cere-
bral malaria. On the basis of these observations, we hypothesized
that PlasmodiumHMGBproteinsmight act in a proinflammatory
and vasoactivemanner and thus be involved in the pathogenesis of
severe forms of malaria, including CM. We showed that the in-
volvement of the hmgb2 gene in the pathogenicity of the parasite is
governed by the parasite itself—P. berghei ANKA or P. berghei
NK65—in addition to the mouse strain—C57BL/6 or BALB/c—
highlighting the importance of the host/parasite context. Most
importantly, we provide evidence showing that this is indeed the
case, using an ECM model comprising the ECM-sensitive
(ECM-S) mouse line C57BL/6 infected with either the highly
lethal strain Plasmodium berghei ANKA or its pbhmgb2-deficient
cognate, hmgb2 ANKA. The involvement of pbhmgb2 in ECM
was also studied via supplementation experiments with the re-
combinant PbHMGB2 protein.
MATERIALS AND METHODS
Ethics statement. All animal care and experiments involving mice de-
scribed in the present study were approved by the DirectionDépartemen-
tale des Services Vétérinaires de Paris, France (permit A75-13-01), and
performed in compliance with institutional guidelines and European reg-
ulations (http://ec.europa.eu/environment/chemicals/lab_animals/home
_en.htm). All surgery was performed under sodium pentobarbital anes-
thesia, and all efforts were made to minimize suffering.
Mice. C57BL/6 and BALB/c mice were purchased from Janvier and
Charles River Laboratories, respectively.
Parasites. Mice were inoculated with red blood cells (RBCs) infected
with either green fluorescent protein (GFP)-transgenic P. berghei ANKA
(MRA-867) orhmgb2ANKA parasites and, occasionally, with P. berghei
NK65 (MRA-268) and its hmgb2-deficient counterpart.
Murine model of ECM. In all experiments, RBCs infected with P.
berghei ANKA or its knockout counterpart were used to infect 5- to 10-
week-old C57BL/6 or BALB/c mice. Parasites were reactivated before ev-
ery experiment by previous passages in ECM-SC57BL/6mice. Depending
on the experiment, C57BL/6mice were then infected by intravenous (i.v.)
or intraperitoneal (i.p.) inoculation of 105 pRBCs. Parasitemia was deter-
mined by flow cytometry and the results expressed as the percentage of
pRBCs. C57BL/6 mice infected with P. berghei ANKA or hmgb2 ANKA
supplemented with recombinant PbHMGB2 were monitored for clinical
symptoms of ECM, including hemi- or paraplegia, deviation of the head,
the tendency to roll over on stimulation, ataxia, and convulsions.
Protein preparation. Escherichia coli BL21(DE3)/pLysS (Stratagene)
was used to express the PbHMGB2 protein from the pEXP5-CT/TOPO
(Invitrogen) construct. The pbhmgb2 open reading frame (ORF) was am-
plified by PCR from P. bergheiANKA cDNA by using the following oligo-
nucleotides: pbhmgb2 forward, 5=ATGGCAACTAAAACACAAAA3=; and
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pbhmgb2 reverse, 5=TTATTCCTTGGTTTTTCTATATTCT3=. The stop
codon was removed from the reverse primer to allow cloning into the
pEXP5-CT/TOPO vector, in which a 6-His tag was added at the C termi-
nus of the protein. Overnight cultures were used to inoculate 2YT me-
dium containing appropriate antibiotics. Cultures were shaken at 230
rpm until the A600 reached 0.6. Protein expression was then induced for 4
h at 37°C by the addition of 1 mM IPTG (isopropyl--D-thiogalactopyra-
noside). The bacteria were then harvested by centrifugation for 20 min at
4,000 rpm and stored frozen at20°C.
PbHMGB2 was purified using a protocol adapted from a previous
study (51). Bacteria were suspended in 1ml of lysis buffer (1	 phosphate-
buffered saline [PBS], 10mM -mercaptoethanol, 0.5% Triton X-100, 10
mM imidazole) per 0.5 g of bacterial pellet, with a pinch of lysozyme.
Bacteria were disrupted by sonication (Branson sonifier 450) at 10 W 10
times for 20 s each, with 20-s pauses, and centrifuged for 25min at 10,000
rpm and 4°C. The supernatant was collected and loaded onto Ni-nitrilo-
triacetic acid (Ni-NTA) agarose beads (Qiagen) which were previously
equilibrated in 5ml of washing buffer 1 (1	 PBS, 20mM imidazole, 0.1%
Triton X-114). Triton X-114 was added to this washing buffer to remove
contaminating lipopolysaccharide (LPS). The mixture was rotated on a
wheel for 2 h at 4°C. Wet beads (0.2 ml per 1 ml of lysate) were incubated
for 2 h. Beads were centrifuged thereafter at 4°C and 3,000 rpm for 3 min
and then washed 3 times for 10 min each with 25 volumes of washing
buffer 1 and then 2 times for 10 min each with 10 volumes of washing
buffer 2 (1	PBS, 30mM imidazole) to remove the residual TritonX-114.
Protein elution was achieved by using 1	 PBS containing 150 mM to 200
mM imidazole. The recombinant protein concentration and purity were
assessed by spectrophotometric quantitation (Bio-Rad protein assay) and
12% SDS-PAGE. The presence of residual endotoxin in the proteins was
checked by using an E-toxate kit (Sigma) following the manufacturer’s
instructions.
Disruption of the pbhmgb2 gene. We describe here the strategy for
hmgb2 gene disruption (PBANKA_071290) that was used for the P. ber-
ghei ANKA and P. berghei NK65 parasites. Two PCR fragments flanking
the HMGB2 ORF were amplified from the genomic DNA by using the
oligonucleotides listed in Table S1 in the supplemental material. Ampli-
fication of the 5=-untranslated region (5=UTR) with the primer combina-
tion 5=-hmgb2-for and 5=-hmgb2-rev, includingApaI and SmaI restriction
sites, respectively, resulted in a 526-bp fragment which was cloned up-
stream of the positive selection marker, the human dihydrofolate reduc-
tase gene (hudhfr), previously introduced into the pBC SK-vector (Strat-
agene) under the control of the EF1 promoter and the dhfr/ts
(dihydrofolate reductase/thymidylate synthase) 3=UTR. Next, the 3=UTR
region was amplified with the 3=-hmgb2-for and 3=-hmgb2-rev primers,
including NotI and AscI restriction sites, respectively. This fragment was
inserted downstream of the hudhfr box, resulting in the hmgb2 targeting
vector pBC-5=B2hudhfr3=B2, allowing replacement of the endogenous
hmgb2 locus in P. berghei ANKA upon double-crossover homologous
recombination and subsequent selection with the antifolate pyrimeth-
amine (52). P. berghei parasite transfections were performed with 5 
g
ApaI/AscI-digested pBC-5=B2hudhfr3=B2 and gradient-purifiedP. berghei
ANKA schizonts as described previously (53). Positive selection for suc-
cessful integration of the targeting plasmid was carried out by providing
70 
g/ml of pyrimethamine in drinking water for a period of 8 days.
Transfer of the emerging P. berghei population into naive animals con-
firmed pyrimethamine resistance. Genomic DNAs from selected parasite
populationswere genotyped by an integration-specific PCRusing primers
dhfr-for and hmgb2-anarev (see Table S2 in the supplemental material).
Clonal hmgb2-deficient parasite populations were obtained by limiting
dilution in 20 naive Swiss mice and confirmed by diagnostic PCR and
Southern blotting. A probe spanning the 5=-hmgb2 portion was amplified
by PCR and digoxigenin-dUTP (DIG) labeled using a DIG randomprime
labeling kit (Roche Applied Science). Southern blotting was performed
after running 4 
g of MstI-digested genomic DNA on a 0.8% agarose gel,
with passive transfer to a nitrocellulose membrane, and the DNA was
revealed using an anti-DIG antibody coupled to peroxidase (Roche Ap-
plied Science).
Supplementation with recombinant proteins. We assessed the best
concentration of protein capable of restoring ECM in mice according to
the data reported for recombinant HMGB1 (54). C57BL/6 mice infected
with 105hmgb2ANKApRBCswere injected by i.p. inoculation fromday
4 to day 8 postinfection (p.i.), using 25 mg of PbHMGB2/kg of body
weight twice a day (every 12 h). According to the LPS contamination of
the protein preparations (25 ng or 50 ng per protein injection), control
infected C57BL/6 mice were inoculated following the same procedure,
with the protein elution buffer containing the same concentrations of
LPS. Also, uninfected C57BL/6 mice were injected with recombinant
PbHMGB2 alone to assess the lack of toxicity of the recombinant protein.
Evaluation of parasite burdens by cytometry and Giemsa counting.
The growth of wild-type (WT) P. berghei ANKA and derived mutant par-
asites was determined by flow cytometry using an Epics XL Beckman flow
cytometer as described previously (53). Experiments were repeated three
times, and statistical analysis was performed using the Student t test.
Growth of WT P. berghei NK65 and derived mutant parasites was deter-
mined bymicroscopic examination of Giemsa-stained thin blood smears.
Parasitemia was measured by counting 3,000 red blood cells and ex-
pressed as the percentage of total parasitized erythrocytes.
Histological analysis. Brains from P. berghei ANKA- and hmgb2
ANKA-infected C57BL/6 mice were removed at specific time points of
infection, fixed in 4% neutral buffered formalin for 4 days, and then
dissected and embedded in paraffin. For each brain, five transversal large
sections, each 2mm thick, from the brain stem to the olfactory bulb, were
removed before being embedded in five paraffin blocks. For each paraffin
block, serial 5-
m sections stained with hematoxylin and eosin and Gi-
emsa stain were studied, and this protocol correlated with a total of 20
sections for each mouse brain (modified from the protocol described for
themouse brain in stereotaxic coordinates [55]). Elementary lesions were
studied according to the following criteria: hemorrhages,malaria pigment
deposition, and attachment of red and white blood cells to the endothe-
lium. A hemorrhagic focus was defined as a minimal surface of a 10- by
10-
m square, malaria pigment was observed only in infected red cells,
and adhesion inmurine animalmodels was observed only for white blood
cells, in contrast to human pathology.
BBBpermeability.C57BL/6mice infected with P. bergheiANKAwere
injected retro-orbitally with 0.1ml of 2% (wt/vol) Evans blue (EB) in PBS
when clinical symptoms of ECM were observed (head deviation, convul-
sions, ataxia, and paraplegia), usually on days 6 to 8 p.i. hmgb2 ANKA-
infected C57BL/6 mice were injected following the same protocol at the
same time, and also later on (day 12 p.i.), in cases of survival. One hour
later,micewere perfusedwith 20ml PBSunder anesthesia (0.5ml xylazine
[Rompun], 1 ml ketamine [Imalgène 1000], quantity sufficient for 4 ml
1	 PBS), and brains were harvested and photographed.
In the protein supplementation experiments, the brains of mice in-
fected with either WT or knockout (KO) parasites, supplemented or not
with recombinant HMGB2, were harvested as depicted above, weighed,
and incubated in 2 ml formamide for 48 h at 37°C and in the dark. The
quantification of BBB disruption was evaluated by measuring the absor-
bance at 620 nm, with a correction at 740 nm. The amount of Evans blue
that infiltrated the brain was measured by comparison with a standard
curve of Evans blue in formamide.
Preparation of total RNA and reverse transcription-quantitative
PCR (RT-qPCR) transcript analysis.At different times postinfection, to-
tal RNAs were extracted from brains, spleens, and lungs removed from
C57BL/6 mice infected with either P. berghei ANKA or hmgb2 ANKA
parasites. RNA preparation was performed between days 6 and 8 (coma
stage) and at day 12 postinfection, i.e., the last day analyzed (survival).
Total RNAs were extracted from the samples by mechanical grinding us-
ing TRIzol (Invitrogen) following the manufacturer’s instructions. Con-
taminant DNA and proteins were removed following Qiagen’s protocol
for RNA cleanup (Qiagen RNeasy kit), and the integrity of the RNAs was
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controlled by using a Bioanalyzer 2100 instrument (Agilent Technolo-
gies).
The expression levels of diverse transcripts were analyzed by real-
time RT-qPCR in an MX 3005P cycler (Stratagene), using SYBR green
Jumpstart TaqReadyMix (Sigma) and various primer sets (see Table S2
in the supplemental material). Murine hmgb transcripts as well as
transcripts of diverse pro- and anti-inflammatory cytokines and cellu-
lar adhesion molecules (cams) were monitored as follows. Reverse
transcription of 1 
g total RNA was performed using a Superscript
VILO cDNA synthesis kit (Invitrogen) according to the manufactur-
er’s instructions. Five microliters of a 1/10 dilution of each cDNA was
amplified with a 200 nM concentration of every primer set and 10 
l of
SYBR green in a final volume of 20 
l. Amplification conditions com-
prised initial denaturation at 95°C for 2 min followed by 40 cycles of
denaturation for 30 s at 95°C and annealing-elongation for 60 s at
60°C. The specificity of the reaction was controlled by the generation
of a dissociation curve with 36 cycles of 30 s, starting at 60°C, with an
increment of 1°C every cycle. The relative expression levels of tran-
scripts were evaluated against that of uninfected C57BL/6 mice and
normalized for each RNA sample with the hypoxanthyl-guanine phos-
phoribosyltransferase (hprt) transcript.
Preparation of brain and spleen cell suspensions. Brains and spleens
were obtained from wild-type P. berghei ANKA- or hmgb2 ANKA-in-
fected C57BL/6 mice at the coma stage of CM (day 6 [d6]). Briefly, mice
anesthetized with ketamine (600 mg/kg) and xylazine (20 mg/kg) were
perfused with 50 ml of PBS. Each brain was then removed and homoge-
nized in RPMI 1640 medium (BioWhittaker, Walkersville, MD) by pas-
sage through sterile meshes to obtain a single-cell suspension. To harvest
leukocytes from brain tissue, Percoll (Pharmacia Biotech, Uppsala, Swe-
den) was added at a final concentration of 35% to the cell pellet and
centrifuged at 400	 g for 20min at 20°C. The cell pellet was washed twice
and analyzed via flow cytometry.
Flow cytometric analysis of brain and spleen leukocytes. Spleen and
brain cells were stained for fluorescence-activated cell sorter (FACS) anal-
ysis according to standard protocols in cold PBS containing 2% fetal calf
serumand 0.01% sodiumazide (FACSbuffer)with the following antibod-
ies: allophycocyanin (APC)-labeled CD4, fluorescein isothiocyanate
(FITC)-labeled anti-CD8, FITC-labeled anti-F4/80 antibody, phyco-
erythrin (PE)-labeled anti-Ly6G antibody, PE-labeled anti-granzyme B
antibody, and PE-labeled anti-IFN- antibody. All antibodies were pur-
chased from eBioscience, San Diego, CA. RBCs were eliminated using cell
lysis buffer, and cells were washed in FACS buffer. Living cells of the brain
and spleen (4 	 104 and 105, respectively) were analyzed using a four-
color FACSCalibur flow cytometer with ProCellQuest software (BD Bio-
sciences, Mountain View, CA).
Enzyme-linked immunosorbent assay (ELISA) detection of
PbHMGB1 and PbHMGB2 proteins in the sera of mice. Serum samples
were obtained from naive or infected C57BL/6 mice inoculated with the
WT or hmgb2 ANKA strain. Titrations of PbHMGB1 and PbHMGB2
were performed using the protocol described by Barnay-Verdier et al.
(56), with slightmodifications. Themajority of serumproteins other than
PbHMGB1 andPbHMGB2were removed by precipitation in the presence
of 3% perchloric acid (PCA), as follows. A stock solution of 13.7% PCA
was prepared by mixing a 1.26 volume of 70% PCA (the concentration of
PCA sold commercially) with 8.69 volumes of H2O. The stock solution
was stored in a tinted bottle sealed at room temperature. To 1 volume of
serum (or other test sample) on ice, a 1/4 volume of 13.7%PCAwas added
and mixed well. A solution of 3% PCA led to the immediate formation of
an abundant precipitate. The sample was immediately centrifuged for 5
min at 13,000 	 g at 4°C. A known volume of the supernatant, which
contained the PbHMGB proteins, was collected and neutralized by addi-
tion of a 1/5 volume of 1.5 M NaOH. In our experience, 200 
l of super-
natant was neutralized with 17 
l of 10 M NaOH. Since the process of
precipitation/neutralization led to an increase in volume of 50% due to
the addition of the reagents, 1.5 
l of the neutralized supernatant was
tested to measure the concentration of PbHMGB in 1 
l of serum. A
volume (50 
l) diluted 1/4 was added to a 96-well plate precoated with
rabbit anti-PbHMGB1 or anti-PbHMGB2 IgG antibody and incubated
for 2 h at 37°C. After saturation with 100 
l of 1% bovine serum albumin
(BSA), the wells were washed, and biotin-labeled rabbit anti-HMGB1 or
anti-HMGB2 IgG was added at a predefined dilution of 1/250 and incu-
bated for 2 h at 37°C. Afterwashing, 50
l was added to eachwell, followed
by streptavidin-peroxidase. The reaction was revealed by adding ortho-
phenylenediamine plus H2O2.
Statistical analysis.Differences inmouse survival were evaluated by
the generation of Kaplan-Meier survival plots and log rank analysis.
Differences in growth rates (peripheral parasitemia) and parasite loads
were analyzed by the Student t test. Kruskal-Wallis analysis was per-
formed to compare means between the 3 or 4 groups of data for hem-
orrhagic focus numbering, survival curves, BBB disruption evaluation,
brain- or spleen-infiltrating T-cell numbering, and transcript expres-
sion levels. Dunn’s posttest was applied to analyze the effect of
pbhmgb2 deletion. P values of 0.05 were considered statistically sig-
nificant for each test.
Nucleotide sequence accession numbers. The sequences of the P.
berghei high-mobility-group protein gene pbhmgb2 (PBANKA_071290)
and theP. bergheiANKA rRNA-encoding gene berg06_18s are available in
PlasmoDB (http://plasmodb.org/plasmo/). Mouse gene sequences are
available in NCBI GenBank under the following accession numbers:Mus
musculus hypoxanthine guanine phosphoribosyltransferase (Hprt),
NM_013556.2; M. musculus high-mobility-group protein 1 (muhmgb1),
NM_010439.3; M. musculus high-mobility-group protein 2 (muhmgb2),
NM_008252.3; M. musculus tumor necrosis factor alpha (tnf),
NM_013693.2; M. musculus interleukin 6 (il-6), NM_031168.1; M. mus-
culus gamma interferon (ifn), NM_008337.3;M.musculus interleukin 10
(il-10), NM_010548.2; M. musculus intercellular adhesion molecule 1
(icam1), NM_010493.2; M. musculus vascular adhesion molecule 1
(vcam1), NM_011693.3; and M. musculus heme oxygenase 1 (hmox1),
NM_010442.2.
RESULTS
PlasmodiumHMGB proteins are released into the extracellular
milieu. To explore the systemic biological effect of HMGB2 on
Plasmodium pathogenicity, our working hypothesis was based on
the secretion of this “alarmin” protein from the parasite. We de-
termined the occurrence of the P. berghei rodent parasite protein
(PbHMGB2) in the sera of C57BL/6 mice infected with wild-type
P. berghei ANKA via ELISA titration (Fig. 1). As expected, the
protein was not found in the sera of naive noninfected mice but
FIG 1 Release of the HMGB2 protein into the extracellular milieu. Release of
P. berghei ANKA (PbANKA) HMGB2 into the sera of mice was analyzed by
ELISA. C57BL/6 mice were inoculated with 105 erythrocytes infected with
eitherhmgb2 orWT P. bergheiANKA parasites. Sera of four mice were taken
at d7 postinfection and tested for their HMGB2 content by ELISA. Sera from
naive mice were taken as negative controls. Results shown in the figure are
expressed in nanograms per milliliter, as determined by a titration curve ob-
tained using a range of concentrations of recombinant HMGB2.
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was present in mice infected by theWT P. berghei ANKA parasite,
i.e., the rodent model of ECM (as PbHMGB1) (data not shown).
Parasite multiplication and ECM occurrence are generated
differently according to the host-parasite strain context. We
studied the implications of the HMGB2 protein in several parasite
and murine strains. We used two highly pathogenic P. berghei
parasites, P. berghei ANKA and P. berghei NK65, leading to the
death of mice within 7  1 days per ECM or 20 to 25 days per
hyperparasitemia, respectively. Actually, two strains of mice,
known to be susceptible to ECM (ECM-S) (C57BL/6 mice) or
resistant to ECM (ECM-R) (BALB/c mice), were infected by the
two WT parasites, and the effects of addition of the recombinant
HMGB protein were investigated (Fig. 2A to D). The occurrence
of ECM is dependent on the host-parasite combination (summa-
rized in Table 1).
In the ECM-R BALB/c mice, P. berghei ANKA parasites devel-
oped with a complete absence of neurological symptoms associ-
ated with ECM, thereafter leading to death via hyperparasitemia
(Fig. 2B). However, injection of recombinant PbHMGB2 (see de-
tails in Materials and Methods) into these ECM-R mice induced
the death of mice (60%) within 7 to 9 days p.i., with neurological
symptoms (Fig. 2A). We verified that the protein alone was not
pathogenic and therefore that ECM did not rely on the toxicity of
the proteins.
In the ECM-S C57BL/6 mice, the P. berghei NK65 parasite de-
veloped in the absence of neurological symptoms (Fig. 2C, vehicle
control). Supplementation with the PbHMGB2 protein did not
induce ECM (Fig. 2C), and P. berghei NK65 multiplication was
not affected (Fig. 2D).
We generated hmgb2-deficient P. berghei ANKA and P. berghei
NK65 parasites (hmgb2 ANKA andhmgb2NK65) as described
in Fig. S1 in the supplemental material. The asexual development
of the P. bergheiANKA and P. bergheiNK65 strains, as well as their
hmgb2-deficient derivatives, was studied in the twomouse strains.
In ECM-R BALB/cmice, themultiplication of theWTwas similar
to that of the KO P. berghei ANKA parasite (Fig. 2E). In ECM-S
C57BL/6mice, themultiplication levels of theP. bergheiNK65 and
hmgb2NK65 parasites appeared to be different: whereas theWT
FIG 2 Multiplication of diverse WT and hmgb2-deficient parasites according to the host mouse strain. (A and B) Survival (A) and parasitemia (B) of
BALB/c mice infected with WT P. berghei ANKA and supplemented or not from days 4 to 8 p.i. (dashed line) with either recombinant PbHMGB2 (25 mg/kg)
or vehicle (protein buffer plus 50 ng LPS, which takes into account the residual LPS contamination of the recombinant protein) twice a day (every 12 h). All mice
were injected i.v. with 106 red blood cells infected withWT P. bergheiANKA. Differences in mortality/survival betweenWT-infected mice, supplemented or not
with PbHMGB2, were analyzed by the log rank test. (C and D) Survival (C) and parasitemia (D) of C57BL/6 mice infected with WT P. berghei NK65 and
supplemented with recombinant PbHMGB2 as described above. All mice were injected i.v. with 105 red blood cells infected withWT P. bergheiNK65. For panels
A to D, groups of mice contained five mice each. (E and F) Red blood cell development of P. berghei ANKA (E) and P. bergheiNK65 (F), as well as their hmgb2
counterparts, in infected BALB/c andC57BL/6mice, respectively. Parasitemia wasmeasured by flow cytometry (E) andGiemsa counting (F) for sets of fivemice.
Values representmeans standard deviations (SD) for one representative experiment of three. Statistical analyses of parasitemia were performed by the Student
t test.
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parasitemia increased for up to 15 days or more, the multiplica-
tion of hmgb2 NK65 parasites increased and then decreased
thereafter for 15 days, when it was no longer detected in the pe-
ripheral blood (Fig. 2F). Indeed, the hmgb2 gene disruptionmod-
ified the fitness of the parasite, since from similar multiplication
levels at early times p.i., the hmgb2-deficient P. berghei NK65
parasites were ultimately cleared from the peripheral blood.
Finally, in the ECM-S C57BL/6 mice, P. berghei ANKA and
hmgb2ANKA parasites developed differently (see the next para-
graph). Only P. berghei ANKA infection triggered ECM in
C57BL/6 mice, in contrast to all combinations just mentioned
(Table 1). We therefore decided to focus our study on the impli-
cations of HMGB2 in the occurrence of ECM by the use of
C57BL/6 mice infected with P. berghei ANKA WT and hmgb2-
deficient parasites.
Deletion ofPlasmodiumhmgb2 protects C57BL/6mice from
an ECM outcome. As just mentioned, the rodent ECM model
used in the following experiments showed the death of C57BL/6
mice within 6 to 7 days p.i. when mice were i.p. injected with 105
red blood cells infected with P. bergheiANKA (Fig. 3A).We inves-
tigated the role of the HMGB2 protein in experimental cerebral
malaria via deletion of the gene from the parasite. A targeting
construct was generated, i.e., pBC-5=B2hudhfr3=B2, that, after
double-crossover homologous recombination, inserts the
huDHFR selectable cassette in place of the Plasmodium berghei
ANKA hmgb2 locus. After transfection of the linearized pBC-
5=B2hudhfr3=B2 plasmid into P. berghei ANKA merozoites, re-
combinant parasites were selected and cloned (see Fig. S1 in the
supplemental material). pbhmgb2 gene disruption in P. berghei
ANKA parasites was verified in three independent clones. When
the ECM-S C57BL/6 mice were infected with these three clones,
we observed that the clones differed from the wild-type parasites
in their lethality and occurrence of ECM (see Fig. S2). Indeed, a
marked increase in survival from ECM was observed, with sur-
vival of up to 100% at d20 p.i., depending on the clone tested. We
selected clone F, which we named the hmgb2 ANKA strain, to
perform all subsequent analyses. Actually, PbHMGB2was not de-
tected in the sera ofmice infectedwithhmgb2ANKA, in contrast
to the sera ofmice infected withWT P. bergheiANKA (Fig. 1), nor
was the hmgb2 transcript (see Fig. S1). Using the same procedure,
nohmgb1 parasites were obtained after three independent trans-
fections, suggesting that the gene is essential for parasite develop-
ment.
The survival and peripheral parasitemia of mice infected by
eitherWT P. bergheiANKA orhmgb2ANKAwere monitored in
three independent experiments. As expected, all mice infected
(i.p.) withWT P. bergheiANKA died within 6 to 7 days (d6 to d7).
In contrast, deletion of the hmgb2 gene was associated with a
reduction of ECM incidence, with 65% 10.67% (mean stan-
dard error of the mean [SEM]) (P 0.0001) of mice not develop-
ing ECMand succumbing 20 days after infection fromhyperpara-
sitemia, a lethal outcome of P. berghei ANKA that is unrelated to
ECM (Fig. 3A). Both strains developed similar peripheral para-
sitemias for up to 6 days, as evaluated by the percentage of para-
sitized red blood cells (Fig. 3B). The hmgb2 ANKA parasite
maintained its development until d20, leading to the death of
C57BL/6 mice later by severe anemia and hyperparasitemia. To
confirm that the lack of ECM onset in hmgb2 ANKA-infected
micewas not due to an alteration of parasite growth, we compared
the asexualmultiplication rates of both parasites. The cloning pro-
cedure described by Janse and colleagues (53) was achieved at d6
by counting Giemsa-stained blood smears. The mean asexual
multiplication rate at 24 hwas calculated by assuming a total of 1.2
	 1010 erythrocytes/mouse and resulted in values of 11.94  0.7
and 11.66  0.2 for WT P. berghei ANKA and hmgb2 ANKA,
respectively. The asexualmultiplication of theKOparasitewas not
reduced compared to that of the WT parasite, underlining the
identical growth rate of the knockout parasites.
Deletion ofPlasmodiumhmgb2 protects C57BL/6mice from
blood-brain barrier damage. Suppression of ECM in C57BL/6
mice infected with hmgb2 ANKA was associated with reduced
brain damage, as assessed by the extent of microvascular hemor-
rhages, andwith reduced parasite sequestration. As early as d5 p.i.,
prior to ECM manifestation, no apparent brain damage was ob-
served in hmgb2 ANKA-infected C57BL/6 mice, whereas mini-
mal hemorrhages were already noticeable in 20% of mice infected
with WT parasites (data not shown). P. berghei ANKA-infected
C57BL/6 mice exhibited extended and severe hemorrhagic foci at
d6 to d8 after infection (Fig. 3C, top row),whilemice infectedwith
the mutant parasite displayed moderate hemorrhagic foci (Fig.
3C,middle row). In an additional experiment, there was amarked
decrease in the number of hemorrhagic foci per histological brain
section at d6 and d7 p.i. (P 0.05) for each time point between P.
berghei ANKA and hmgb2 ANKA (Fig. 3D). Finally, at d12 p.i.,
mice surviving hmgb2 ANKA infection did not exhibit either
hemorrhages or cerebral lesions (Fig. 3C, bottom row). These ob-
servations were confirmed by BBB disruption, as illustrated by
Evans blue leakage in the brains of WT P. berghei ANKA-infected
mice, whereas this was not apparent in brains of hmgb2 ANKA-
infected mice (Fig. 3C, right column).
TABLE 1 Occurrence of ECM according to host-parasite strain context
P. berghei strain
Presence of
PbHMGB2 protein
Occurrence of ECMa
C57BL/6 mice BALB/c mice
WT P. berghei ANKA  †, 100% ECM No ECM, 100% death by hyperparasitemia
 ND †, 65% ECM
KO P. berghei ANKA  65% ECM survival No ECM, 100% death by hyperparasitemia
 †, 65% ECM
WT P. berghei NK65  No ECM, 100% death by hyperparasitemia ND
 No ECM, 100% death by hyperparasitemia ND
KO P. berghei NK65  No ECM, no death by hyperparasitemia, 100% survival ND
 ND ND
a †, death of mice; ND, not determined.
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Exogenous PbHMGB2 protein restores hmgb2 ANKA vir-
ulence. To ascertain that the increased resistance to ECM in
C57BL/6 mice infected with hmgb2 ANKA versus WT P. berghei
ANKA was due at least in part to the lack of extracellular
PbHMGB2, we assessed whether recombinant PbHMGB2 was
sufficient per se to reestablish ECM susceptibility in hmgb2
ANKA-infected mice.
Recombinant PbHMGB2 restored the incidence of ECM in
hmgb2 ANKA-infected mice, i.e., 60% of mice died of ECM at
d10, with cerebral symptoms (Fig. 4A). This experiment, which
was analyzed by the Kruskal-Wallis test (P  0.0025), was re-
peated 3 times with 10 mice per group. A statistical difference was
observed from d10 to d20 postinfection between mice infected
with thehmgb2 ANKA parasite in the absence or presence of the
PbHMGB2 protein as analyzed by the Student t test (P 0.0012).
The pathological effect of PbHMGB2 was not associated with a
modulation of peripheral parasitemia (Fig. 4B), since the parasite
fitness was not affected. Moreover, a low ECM incidence was ob-
served for vehicle-treatedC57BL/6mice infectedwith thehmgb2
ANKA strain (30% death), as in controls, suggesting that the
low level of LPS contamination did not account for the ECM in-
crease observed when PbHMGB2 was injected into mice. These
observations were confirmed by the BBB permeability. Figure 4C
shows a histogram for Evans blue evaluation of the brains of mice
infected withhmgb2ANKA and complemented with the recom-
binant protein compared to the brains of control mice infected
with the hmgb2-deficient parasite alone or in the presence of ve-
hicle. The recombinant PbHMGB2 preparations produced in E.
coli contained less than 100 ng LPS per mg of recombinant pro-
tein. This residual LPS contamination was used as a vehicle con-
trol in these experiments. A statistical difference in BBB disrup-
tion was observed between the brains of hmgb2 ANKA- and
complemented hmgb2 ANKA-infected mice (P 0.0008).
Resistance of mice to development of ECM following infec-
tion with hmgb2 ANKA correlates with a reduction of brain-
infiltrating T cells. The development of CM is strongly associated
FIG 3 Comparative analyses of C57BL/6 mice infected with WT P. berghei ANKA and hmgb2 ANKA parasites. (A) Kaplan-Meier survival plot for C57BL/6
mice infected with either 105WT P. bergheiANKA orhmgb2ANKA parasites. Infectedmice weremonitored every day, starting on d5 p.i., for ECM symptoms.
The difference in survival between WT- and hmgb2 ANKA-infected C57BL/6 mice was analyzed by the log rank test. This experiment was performed 3 times
(n 4,n 7, andn 9). (B) Parasitemia of both parasites asmeasured by flow cytometry. Values representmeans SD. (C)Histological analyses of brains from
WT- andhmgb2ANKA-infected C57BL/6mice. The images show representative hematoxylin- and eosin-stained sagittal sections of brains harvested at d6 and
d12 p.i. fromWT (d6, panels 1 to 3)- andhmgb2ANKA (d6, panels 5 to 7; d12, panels 9 to 11)-infected C57BL/6mice (n 5 for each experimental group). The
black arrows indicate the hemorrhagic foci. In each row, two incremental magnifications of the same microscopic field are presented. Evans blue dye leakage in
brains ofWT (d6, panel 4)- andhmgb2ANKA (d6, panel 8; d12, panel 12)-infected C57BL/6mice is presented in the far right column. (D)Microscopic counts
of the numbers of hemorrhagic foci per histological brain section at d6 and d7 p.i. (n 5 for each experimental group). Multiple comparisons of focus numbers
were analyzed by the Kruskal-Wallis test (with Dunn’s multiple-comparison test; P 0.0008).
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with the activation and recruitment of T cells in the brain (21, 22).
Accordingly, we examined whether such T-cell recruitment oc-
curred when mice were infected with hmgb2 ANKA. Brain- and
spleen-infiltrating leukocytes were isolated from naive C57BL/6
mice or mice infected with WT or hmgb2 ANKA 7 days after
infection (Fig. 5). Compared to the uninfected controls, C57BL/6
mice infected with WT P. berghei ANKA displayed marked in-
creases in the numbers of CD4 T cells (7-fold) and CD8 T cells
(64-fold) in the brain (Fig. 5A and B), as expected. In addition,
CD8 GzmB and CD8 IFN- T-cell sequestration (23, 24)
was also increased (18- and 40-fold, respectively) compared to
that in the uninfected mice. Interestingly, the recruitment of
CD4 T cells (2-fold) and CD8 T cells (4-fold) was lower in the
brains ofmice infected withhmgb2ANKA than in those infected
with theWT P. bergheiANKA parasites, as well as the recruitment
of CD8T cells expressingGzmBor IFN- (3.5-fold) (Fig. 5C and
D). To verify whether the lack of the pbhmgb2 gene altered the
CD4, CD8 GzmB, and CD8 IFN- T-cell sequestration in
areas other than the brain, a similar analysis was performed with
the spleens of naive and infectedmice. All data for the spleen were
consistent with those observed for the brain (Fig. 5E, F, and H),
except for CD8 GzmB T cells, whose numbers did not differ
significantly between the two groups (Fig. 5G).
In search of other leukocytes that exert their effector functions
during ECM, we surmised that neutrophils might represent in-
flammatory cells which cause the disease under particular circum-
stances. These cells were indeed shown to be associated with the
disease pathogenesis (57). Accordingly, although the difference
was not statistically significant, the percentage of Ly6G neutro-
phils in the brain was lower inhmgb2 ANKA-infected mice than
in WT-infected mice (see Fig. S3A in the supplemental material).
Analysis of sequestered F4/80macrophages in the brain did not
show any significant difference (see Fig. S3B). Similarly, no differ-
ence could be detected in Ly6G neutrophils (see Fig. S3C) or
F4/80 macrophages (see Fig. S3D) within the spleens of mice
from the two groups.
Do these cellular alterations that are part of the modulation of
the host immune response by the HMGB2 protein correlate with
parasite density (23, 24)? Parasite burdens were measured in the
periphery (parasitemia) and in different tissues, including the
brain, spleen, and lung (Fig. 6).We evaluated the parasite loads by
RT-qPCR, measuring the relative levels of parasite 18S rRNA in
C57BL/6 mice infected by both parasites, using different tissues
taken at d6 to d7 p.i. Even though the peripheral parasitemia of
hmgb2 ANKA-infected mice was comparable to that of WT P.
berghei ANKA-infected mice (Fig. 6D), less parasite sequestration
was noticed in mouse organs at d6 p.i. In the brain (Fig. 6A) and
lung (Fig. 6B), the parasite levels of hmgb2 ANKA were lower
FIG 4 ECM occurrence in hmgb2 ANKA-infected C57BL/6 mice supplemented with recombinant PbHMGB2 protein. (A) Survival analysis of C57BL/6 mice
infected i.p. with 105hmgb2ANKApRBCs and thereafter injected fromdays 4 to 8 p.i. (dashed line)with eitherPbHMGB2 (25mg/kg) or vehicle (protein buffer
plus 50 ng LPS, which takes into account the residual LPS contamination of the recombinant protein) twice a day (every 12 h) (n 10 for each experimental
group; the experiment was done 3 times). C57BL/6 mice were also infected i.p. with 105 WT P. berghei ANKA pRBCs as an ECM positive control. Mice were
monitored for ECM symptoms from d5 p.i. (B) Parasitemia was measured by flow cytometry. Values represent means SD for one representative experiment
of three. (C) The amount of Evans blue dye (BE) that infiltrated the brain was measured as described in Materials andMethods for the three sets of mice (n 5
for each experimental group). Multiple comparisons were analyzed by the Kruskal-Wallis test followed by Dunn’s posttest for analyses of differences in survival
(P 0.0025) and BBB permeability (P 0.0008) between all sets of mice.
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(approximately 5- and 3.5-fold, respectively) than those observed
forWTparasites. In the spleen (Fig. 6C), the parasite loadwas also
lessened, but to a lesser extent (2.5-fold) than in the brain and
lung.
Deletion of Plasmodium hmgb2 decreases cytokine and ad-
hesion protein messenger expression in brains of infected
C57BL/6 mice. The brains of infected C57BL/6 mice harvested at
d6 and d12 (Fig. 3C) were analyzed to evaluate the contributions
of a variety of gene transcripts to the survival of hmgb2 ANKA-
infected C57BL/6 mice. In addition, we performed an additional
transcript analysis (corresponding to Fig. 3D) by focusing our
examination on d6 or d7, at the onset of ECM, and these data were
included in our statistical analyses. The transcripts of the murine
host, i.e., hmgb1 and hmgb2 transcripts, proinflammatory cyto-
kine transcripts (tnf, ifn, and il-6), and anti-inflammatory
(il-10 and hmox-1) and adhesion (icam-1 and vcam-1) protein
transcripts, were analyzed by RT-qPCR with the primer sets listed
in Table S2 in the supplemental material. The levels of all tran-
scripts (except for those ofmuhmgb1 and hmox-1) were increased
at d6 in the brains of WT P. berghei ANKA-infected mice com-
pared to uninfected mice, with the highest magnitude for ifn
(Fig. 7). The levels of these transcripts were also enhanced in the
brains of mice infected by hmgb2 ANKA, but to a lesser extent.
Note that the decreased expression of the aforementioned genes
was statistically significant in these mice compared to the WT
parasite-infected mice. In addition, this decrease was maintained
at d12 postinfection. As already mentioned, two transcripts did
not follow this trend. The hmox-1 transcript, encoding a heme-
degrading enzyme, showed a marked increase in hmgb2 ANKA-
infectedmice at d6, in contrast to the case inWTP. bergheiANKA-
infected mice, and in turn decreased at d12. Also, the muhmgb1
transcript levels were similar in noninfected and infected mice, in
contrast to the expression of the muhmgb2 transcript, which fol-
lowed the common features for all other genes (markedly in-
creased and markedly decreased in mice infected with WT P. ber-
ghei ANKA and in hmgb2 ANKA-infected mice, respectively).
DISCUSSION
The molecular mechanisms underlying the pathogenesis of cere-
bral malaria remain poorly understood. In humans, presumably,
sequestration of parasitized red blood cells in the brain microvas-
culature, in association with the production of inflammatory cy-
tokines and hemoglobin oxidation, is critical for the onset of this
disease. However, resources and opportunities to explore the
physiopathology of this disease in humans are limited and based
mainly on postmortem investigations. Although the murine
model of cerebral malaria does not perfectly match the human
disease, there is substantial evidence that both share common fea-
tures (for a review, see references 27 and 58). Studies of the mech-
anisms underlying the pathophysiology of ECM revealed a num-
ber of proinflammatory proteins implicated in parasitized red
blood cell sequestration and in brain pathology. Being aware that
both host and parasite biological products might combine to trig-
ger ECM,we decided to focus our study on parasite proteins. Only
one pathogen-associated molecular pattern (PAMP), glycosyl-
phosphatidylinositol (GPI), has been reported for several proto-
zoan parasites, including Plasmodium, to elicit a deleterious host
innate immune response. The P. falciparumGPI, via TLR2 and -4,
signals immune cells to produce proinflammatory cytokines and
induce severe malaria.
We were interested in PlasmodiumHMGB proteins to assess if
they might be involved in the development of ECM, since their
human counterparts are involved in a number of inflammatory
disorders. In the P. falciparum genome, genes encoding two
orthologues of human HMGB, annotated PfHMGB1 and
PfHMGB2, are present. As for the mammalian HMGB isoforms,
these two proteins encompass a TNF--activating domain, sug-
gesting that in addition to their involvement in chromatin remod-
eling (49) when released from the parasite into the extracellular
milieu, they might also, like their mammalian counterparts, act as
genuine inflammatory agonists. In Fig. S4A in the supplemental
material, multiple-sequence alignments of different eukaryotic
HMGB protein domains underline their conserved trait and the
strong conservation between the Plasmodium proteins, with a
higher conservation observed for box B of the mammalian pro-
teins. In addition, alignment of the 20-amino-acid sequences of
the TNF--activating domains (see Fig. S4B) emphasizes the
greater homology encountered between the Plasmodium se-
quences and that of box B of the mammalian proteins (45% iden-
tity and 80% homology), reported to bear the proinflammatory
activity. In keeping with this notion, P. falciparum HMGB pro-
FIG 5 Reduced infiltration and reduced activation of CD4 and CD8 T cells
in the brains ofhmgb2ANKA-infectedmice. At the coma stage (day 6 postin-
fection), brains fromWT- orhmgb2ANKA-infected C57BL/6mice, with 105
infected erythrocytes per mouse, were taken, and leukocytes associated with
cerebral tissue were analyzed by FACS for the presence of the indicated leuko-
cytes, expressed as absolute numbers per brain. Six mice per group were used.
Values represent the means SD for one experiment of three. *, P 0.05; **,
P  0.01; ***, P  0.001; N.S, not significant. (A to D) CD4, CD8, CD8
GzmB, and CD8 IFN- cells in brains. (E to H) The same cells were also
analyzed in spleens. Multiple comparisons of brain-infiltrating T cells were
analyzed by the Kruskal-Wallis test (with Dunn’s posttest).
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teins are released into culture medium (data not shown), and the
P. berghei proteins are detected in the sera of C57BL/6 mice in-
fected with P. berghei ANKA (Fig. 1). In addition, a recombinant
HMGB protein induced TNF- and L-6 production (50). This
led to the hypothesis that Plasmodium HMGB proteins might be
implicated in the pathogenesis of severe forms of malaria, includ-
ing cerebral malaria.
In order to study the role of HMGB in cerebral malaria, we
constructed hmgb-deficient parasites (P. bergheiANKAandP. ber-
ghei NK65 derivatives) (see Fig. S1 in the supplemental material)
FIG 6 Reduced parasite biomass in the organs of hmgb2 ANKA-infected mice. At d6 postinfection, RNAs were extracted from the brains (A), lungs (B), and
spleens (C) of WT- or hmgb2 ANKA-infected C57BL/6 mice (105 infected erythrocytes per mouse). Bars represent the mean SD parasite loads as evaluated
by relative quantification of the 18S mRNA expression level, normalized via the hypoxanthyl-guanine phosphoribosyl transferase (hprt) transcript. Gray bars,
WT P. berghei ANKA-infected mice; black bars, hmgb2 ANKA-infected mice. (D) Parasitemia was measured by counting after Giemsa staining. Values
represent means SD. Comparisons of parasite biomass and parasitemia were analyzed by the Student t test. **, P 0.01; ***, P 0.001.
FIG 7 Analysis of the expression levels of cytokine, adhesion molecule, and hmgb gene transcripts in the brains of WT- and hmgb2 ANKA-infected C57BL/6
mice. Brains were removed from uninfected (n 10) andWT- and hmgb2 ANKA-infected C57BL/6 mice at d6 (n 14 for each group) and d12 (n 3) p.i.,
and total RNAs were extracted. Bars represent the mean SD relative expression levels of the transcripts analyzed, normalized for each RNA sample via the hprt
transcript. The expression levels of cytokine, cam, and hmgb gene transcripts were evaluated against those of naive C57BL/6mice.White bars, noninfectedmice;
light gray bars, WT P. berghei ANKA-infected mice at d6; dark gray and black bars, hmgb2 ANKA-infected mice at d6 and d12, respectively. Multiple
comparisons of expression levels were analyzed by the Kruskal-Wallis test (with Dunn’s posttest). *, P 0.05; **, P 0.01; ***, P 0.001.
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and investigated their growth and their ability to drive ECM in
C57BL/6 and BALB/c mice. Few studies have reported gene dis-
ruption at the level of erythrocytes in vivo (59–61). In mice, an
absence of the hmgb1 gene is lethal, since hmgb1/mice are not
viable and die a few hours after birth (62). The disruption of
hmgb2 is not lethal, but hmgb2/mice displayed reduced fertility
and a spermatogenesis defect (63). Along the same lines, the twoP.
falciparumHMGB proteins display different cellular localizations
within the parasite. Whereas PfHMGB1 is essentially nuclear
throughout the asexual erythrocytic cycle, PfHMGB2 is expressed
predominantly in gametocytes and is present in the nucleus aswell
as in the cytoplasm. The two proteins also differ in their nuclear
activities, with PfHMGB1 being more efficient and specific than
PfHMGB2 for architectural properties (DNA binding and DNA
bending), suggesting that of the two proteins, PfHMGB1 has a
major role in transcription regulation and parasite development
(49). This is consistent with the inability to generate hmgb1 P.
berghei parasites, whereas several clones ofhmgb2 parasites were
obtained.
The pbhmgb2 deletion in P. bergheiANKA induced a reduction
of the ECM incidence in infected ECM-S C57BL/6 mice. The
pathogenic attenuation was not due to a decreased multiplication
of the asexual stage, since the multiplication rate was similar to
that of WT P. berghei ANKA as evaluated in the peripheral blood
(Fig. 3B). Histological analysis of brain sections and EB dye leak-
age showed decreased brain damage already at d6 and d7 postin-
fection compared to WT-infected mice (Fig. 3C and D). A com-
plete absence of hemorrhages was observed in the brains of
surviving mice at d12 p.i. The injection of recombinant
PbHMGB2 into hmgb2 ANKA-infected mice increased the inci-
dence of ECM (up to 60%), thus reestablishing the high mortality
rate observed in susceptible mice (Fig. 4). Moreover, the protein
restored ECM in P. berghei ANKA-infected ECM-R BALB/c mice
(Fig. 2A). In contrast, recombinant HMGB2 was not able to trig-
ger ECM even in ECM-S mice upon infection with the P. berghei
NK65 parasite (Fig. 2C), another lethal parasite that does not in-
duce ECM. The multiplication of P. berghei NK65 parasites in-
creased until the death ofmice by hyperparasitemia, in contrast to
that of thehmgb2NK65parasites, whichwere no longer detected
in the peripheral blood after d15 p.i. (Fig. 2F). In summary, the
involvement of the HMGB2 protein in the pathogenicity of the
parasite is governed by the parasite as well as the mouse strain,
highlighting the importance of the host/parasite context.
For this ECM model, a number of reports have proposed that
sequestration of CD8 and CD4 T cells in the brain capillaries is
a characteristic feature of the brain pathology (21, 22). Recent
studies provided clear evidence that antigen-specificCD8T-cell-
derived granzyme B (23) and CD8 IFN- T cells (26) were
critical in driving cerebral pathology. In addition, a direct causal
link between parasite load and CD8 T-cell-mediated ECM pa-
thology was provided (24). Interestingly, the relationship between
the absence of HMGB2 and the lack of ECM expression was asso-
ciated with a significantly reduced recruitment of CD8 GzmB
and CD8 IFN- T cells in hmgb2 parasite-infected mice. In
addition, the recruitment of CD4 T cells was also decreased,
though to a lesser extent (Fig. 5). This suggests that the lower levels
of CD4, CD8 GzmB, and CD8 IFN- T cells sequestered
within the brain capillaries of mice infected with hmgb2 ANKA
parasites could be the basis of the failure of these mice to develop
ECM. It can also be inferred that HMGB2 exerts systemic effects,
since it appears that sequestration of CD4 and CD8 T cells
rather than neutrophils and macrophages also occurred in in-
flamed spleens.
Very recently, Renia and colleagues (26) observed that CD8T
cells and IFN- drove the rapid increase in total parasite biomass
and accumulation of infected RBCs in the brain and in different
organs at the time when mice developed CM (24). Our data un-
derline that in the absence of HMGB2, the decrease in the recruit-
ment of CD8 GzmB and CD8 IFN- T cells (Fig. 5B to D)
was associated with a reduced recruitment ofhmgb2ANKA par-
asites in the brain (Fig. 6A), in contrast to the similar parasitemia
observed in the peripheral blood, reflecting the identical multipli-
cation rates of the parasites (Fig. 6D). However, even though the
brain was the organ where CD8 T-cell and KO parasite seques-
tration was the most markedly decreased, a decrease was also ob-
served in the lung and spleen (Fig. 5B and C), indicating that
HMGB2 exerts its proinflammatory effects at a systemic level.
Compared to the brains ofWTP. bergheiANKA-infectedmice,
the transcript levels of most proinflammatory cytokines, includ-
ing tnf and ifn, were decreased in the brains ofhmgb2ANKA-
infected mice (Fig. 7). Also, the cell adhesion icam-1 transcript
level was decreased, in contrast to that of vcam-1. In one study,
vcam-1 was identified by microarray analysis as a gene candidate
that discriminates between ECM-R and ECM-S mice in a P. ber-
ghei model (64). Our data do not support the assertion that ele-
vated vcam-1 corresponds to ECM, as we observed slightly higher
vcam-1 mRNA levels in hmgb2 ANKA-infected mice at d6
postinfection than in WT P. berghei ANKA-infected C57BL/6
mice, suggesting an uncertain or perhaps protective role for this
adhesion molecule in our model. In concordance with our obser-
vation of a predominant role for ICAM-1 compared to VCAM-1
in malaria pathogenesis, infusion of an anti-ICAM-1 but not an
anti-VCAM-1 monoclonal antibody prevented cytoadherence of
infected erythrocytes in a P. yoeliimodel of ECM (65), in addition
to in vivo evidence for the role of ICAM-1 in the sequestration of
infected red blood cells in amousemodel of lethalmalaria (66). In
contrast, the transcript level of the cytoprotective heme oxygenase
gene (hmox-1) was markedly increased at d6 in hmgb2 ANKA-
infected C57BL/6 mice and was thus consistent with the literature
(9–11). Our results showing a lower expression level of il-10 tran-
scripts in the brains of hmgb2 ANKA-infected C57BL/6 mice
diverge from other reports on murine CM that suggested a pro-
tective effect for IL-10 in CM (67) but are in accordance with
observations in humans that showed an increase in IL-10 in CM
patients compared tomildmalaria patients (68). Finally, the levels
of murine hmgb1 transcripts did not vary in hmgb2-deficient
ANKA- andWTP. bergheiANKA-infectedmice, in contrast to the
murine hmgb2 transcript levels, which were highly increased in P.
bergheiANKA-infectedmice and remained unchanged inhmgb2
ANKA-infected mice.
Taken together, these data represent a breakthrough in that
Plasmodium HMGB2 is ascribed a major proinflammatory cyto-
kine-like function reminiscent of that of its mammalian HMGB
counterparts, which have been shown to play key roles in several
human diseases, including sepsis, lupus, rheumatoid arthritis, and
cancer (69).
Our data demonstrate that deletion of a single Plasmodium
gene implicated in chromatin remodeling (49) and in inflamma-
tion (50), i.e., hmgb2, contributes to reduced host lethality, an
effect due to suppression of neuropathology. An infected host has
Effect of hmgb2 Gene in Experimental Cerebral Malaria
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two evolutionarily conserved defensive strategies that can limit its
disease severity. One relies on the capacity of its immune system to
reduce the pathogen load, a defensive strategy referred to as resis-
tance to infection. The other defensive strategy acts irrespective of
the pathogen load and relies instead on limiting the extent of tissue
damage caused by the pathogen and/or by the immune response
elicited by that pathogen. This defensive strategy is referred to as
disease tolerance (reviewed in references 70 and 71). The lower
virulence of hmgb2-deficient parasites than wild-type controls is
not associated with modulation of the peripheral pathogen load,
suggesting that PbHMGB2 can compromise disease tolerance to-
ward blood-stage Plasmodium infection. The observation that
protection from ECM in mice infected with hmgb2-deficient par-
asites is reversed by recombinant HMGB2 complementation sug-
gests that it is the soluble PbHMGB2 protein that compromises
the disease tolerance. This finding adds significantly to the previ-
ous observation that free heme generated as an end product of
host hemoglobin oxidation also impairs disease tolerance toward
Plasmodium infection (72). Whether free heme and PbHMGB2
interact functionally to trigger the development of severe forms of
malaria, such as ECM, remains to be established.
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